个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共12条记录   Editorial: Metabolic Therapy: An Important Therapeutic Option for the Treatment of Cardiovascular Diseases [作者：Rosano, GMC; Barbaro, G,期刊：Current Pharmaceutical Design, 页码：2519-2520 , 文章类型： Editorial Material，,卷期：2008年14-25] Cardiac Metabolism in Diabetes Mellitus [作者：Yoshimura, M; Anzawa, R; Mochizuki, S,期刊：Current Pharmaceutical Design, 页码：2521-2526 , 文章类型： Review，,卷期：2008年14-25] Diabetes mellitus is one of the most common chronic illnesses throughout the world. Diabetic cardiomyopathy is a specific syndrome, consisting of cardiomegaly, left ventricular dysfunction, electrical remodeling of the v... Medical Management of the Diabetic Patient with Coronary Artery Disease [作者：Karastergiou, K; Kaski, JC,期刊：Current Pharmaceutical Design, 页码：2527-2536 , 文章类型： Review，,卷期：2008年14-25] The prevalence of type 2 diabetes is rising at an alarming rate worldwide. Coronary artery disease (CAD) is the leading cause of morbidity and mortality in the diabetic population. Future CAD risk should be routinely ass... Optimization of Cardiac Metabolism in Diabetes Mellitus [作者：Vitale, C; Collins, P,期刊：Current Pharmaceutical Design, 页码：2537-2550 , 文章类型： Review，,卷期：2008年14-25] Cardiovascular disease is a major health problem in all over the world. The prevalence of type 2 diabetes mellitus has been rapidly increasing, together with the risk for cardiovascular events. Patients with diabetes, an... Cardiac Metabolism in Myocardial Ischemia [作者：Rosano, GMC; Fini, M; Caminiti, G; Barbaro, G,期刊：Current Pharmaceutical Design, 页码：2551-2562 , 文章类型： Review，,卷期：2008年14-25] Myocardial ischemia occurs for a mismatch between blood flow and metabolic requirements, when the rate of oxygen and metabolic substrates delivery to the myocardium is insufficient to meet the myocardial energy requireme... Modulation of Cardiac Metabolism During Myocardial Ischemia [作者：Chagas, ACP; Dourado, PMM; Galvao, TDG,期刊：Current Pharmaceutical Design, 页码：2563-2571 , 文章类型： Review，,卷期：2008年14-25] Metabolic modulation during myocardial ischemia is possible by the use of specific drugs, which may induce a shift from free fatty acid towards predominantly glucose utilization by the myocardium to increase ATP generati... Physiological Basis for Contractile Dysfunction in Heart Failure [作者：Libera, LD; Vescovo, G; Volterrani, M,期刊：Current Pharmaceutical Design, 页码：2572-2581 , 文章类型： Review，,卷期：2008年14-25] The purpose of this review is to enlighten the mechanisms of skeletal muscle dysfunction in heart failure. The muscle hypothesis suggests that chronic heart failure (CHF) symptoms, dyspnoea and fatigue are due to skeleta... Metabolic Therapy of Heart Failure [作者：Fragasso, G; Salerno, A; Spoladore, R; Bassanelli, G; Arioli, F; Margonato, A,期刊：Current Pharmaceutical Design, 页码：2582-2591 , 文章类型： Review，,卷期：2008年14-25] Alterations of cardiac metabolism can be present in several cardiac syndromes. Heart failure may itself promote metabolic changes such as insulin resistance, in part through neurohumoral activation, and determining an in... The Role of Amino Acids in the Modulation of Cardiac Metabolism During Ischemia and Heart Failure [作者：Marazzi, G; Rosanio, S; Caminiti, G; Dioguardi, FS; Mercuro, G,期刊：Current Pharmaceutical Design, 页码：2592-2604 , 文章类型： Review，,卷期：2008年14-25] During ischemia and heart failure, myocardial cells suffer for chronic energy starvation resulting in metabolic and contractile dysfunction. In normal conditions fatty acids, glucose, and lactate are the principal oxidat... The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome [作者：Fazio, G; Amoroso, GR; Barbaro, G; Novo, G; Novo, S,期刊：Current Pharmaceutical Design, 页码：2605-2612 , 文章类型： Review，,卷期：2008年14-25] Heart Failure (CHF) is a very important public health problem in the world and certainly one of the most common debilitating diseases and cause of mortality. Current knowledge underlines that incidence rates are also inf... Role of Asymmetric Dimethylarginine (ADMA) in Diabetic Vascular Complications [作者：Yamagishi, S; Ueda, S; Nakamura, K; Matsui, T; Okuda, S,期刊：Current Pharmaceutical Design, 页码：2613-2618 , 文章类型： Review，,卷期：2008年14-25] Nitric oxide (NO) is a well-recognized anti-atherogenic factor; it inhibits the inflammatory-proliferative processes in atherosclerosis. Indeed, endothelial dysfunction due to reduced synthesis and/or bioavailability of ... Inhibition of RNA Virus Infections with Peptide-Conjugated Morpholino Oligomers [作者：Stein, DA,期刊：Current Pharmaceutical Design, 页码：2619-2634 , 文章类型： Review，,卷期：2008年14-25] RNA virus infections cause immense human disease burdens globally, and few effective antiviral drugs are available for their treatment. Peptide-conjugated phosphorodiamidate morpholino oligomers (PPMO) are nuclease resis...